Jing Xuquan, Wang Min, Lu Shuangqing, Niu Jiling, Chen Feihu, Yin Hanjing, Liu Haoyu, Sun Dongmei, Zhu Hui
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong Province, China.
BMC Infect Dis. 2025 Jun 2;25(1):779. doi: 10.1186/s12879-025-11172-2.
Cancer patients will have an increased incidence of corona virus disease 2019 (COVID-19) infection. The severity of COVID-19 infection varies among cancer patients who have other complications and are being treated.
This retrospective cohort study evaluated the impact of cancer treatments on COVID-19 incidence and outcomes in 603 cancer patients. Key objectives included assessing treatment-related risks, severity, and treatment efficacy, along with the effects of treatment interruptions on patient recovery and therapy resumption.
This study included 603 cancer patients, of whom 68 (11.28%) were infected with COVID-19, and 398 (66%) were vaccinated. Logistic regression analysis revealed that underlying comorbidities, chemotherapy, and radiotherapy were significantly associated with an increased risk of COVID-19 infection (P < 0.05 for chemotherapy and radiotherapy). Factors such as sex, smoking status, cancer pathology, and staging showed no significant correlation with COVID-19 incidence. Treatment disruptions during the pandemic were observed, with chemotherapy being most affected (42.86% suspension), while surgery and TKI therapy showed minimal interruption. Efficacy analysis indicated no significant difference in treatment outcomes between suspended and uninterrupted treatments (P = 0.758). Treatment suspensions did not significantly alter toxicity profiles, with bone marrow suppression being the most frequent toxicity.
Chemotherapy and radiotherapy increased the risk of COVID-19 in cancer patients, with treatment interruptions not affecting efficacy or toxicity, underscoring the need for tailored management.
癌症患者感染2019冠状病毒病（COVID-19）的发生率会增加。COVID-19感染的严重程度在患有其他并发症且正在接受治疗的癌症患者中各不相同。
这项回顾性队列研究评估了癌症治疗对603名癌症患者COVID-19发病率和结局的影响。主要目标包括评估与治疗相关的风险、严重程度和治疗效果，以及治疗中断对患者康复和治疗恢复的影响。
本研究纳入603名癌症患者，其中68名（11.28%）感染了COVID-19，398名（66%）接种了疫苗。逻辑回归分析显示，基础合并症、化疗和放疗与COVID-19感染风险增加显著相关（化疗和放疗的P<0.05）。性别、吸烟状况、癌症病理和分期等因素与COVID-19发病率无显著相关性。观察到疫情期间治疗中断，化疗受影响最大（42.86%暂停），而手术和TKI治疗中断最少。疗效分析表明，暂停治疗和未中断治疗的治疗结局无显著差异（P=0.758）。治疗暂停并未显著改变毒性特征，骨髓抑制是最常见的毒性。
化疗和放疗增加了癌症患者感染COVID-19的风险，治疗中断不影响疗效或毒性，强调了进行个性化管理的必要性。
